HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction.
HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction.
复制标题
DOI：
10.7150/jca.25184
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Zhou HH
中科院分区：
文献类型：
--
作者：
Luo CH;Zhao M;Chen XY;Shahabi S;Qiang W;Zeng L;Wang J;Zhou HH
对于复发性卵巢癌（ROC），二次细胞减灭术（SCS）是推荐的一种可选治疗方法。然而，对SCS期间生物标志物的表达和临床意义知之甚少。人附睾蛋白4（HE4）是卵巢癌的临床生物标志物。真核翻译起始因子3a（eIF3a）作为恶性肿瘤的潜在生物标志物被广泛研究。本研究的目的是研究ROC患者SCS中HE4和eIF3a的表达及其与手术结果和生存率的关系。应用免疫组织化学方法检测35例ROC患者初次和二次肿瘤细胞减灭术中HE4和eIF3a的表达。与初始细胞减灭术（ICS）相比，SCS时eIF3a水平显著升高，而HE4水平相似。HE4和eIF3a的表达与手术结果有关，在残留肿瘤方面。对于ICS，HE4高表达患者的最佳细胞减灭发生率高于HE4低表达患者（81.0% vs. 33.3%，P = 0.015）。在SCS中也发生了类似的结果，表明HE4高表达患者的无残留肿瘤发生率较高（76.4% vs. 44.4%，P = 0.046）。SCS中HE4高表达更可能提高SCS的手术结局（77.8% vs.29.4%，P = 0.038）。因此，两种手术中HE4的高表达是总生存率（OS）更好的预测因子（P = 0.011和0.002）。此外，与HE4总评分（TS）未升高的患者相比，两次手术之间HE4总评分（TS）升高的患者的OS往往延长（P = 0.076）。对于eIF3a，初始eIF3a表达与继发性残留肿瘤相关（P = 0.035），两次手术之间eIF3a表达的差异与OS相关（P = 0.052）。肿瘤标本中HE4和eIF3a的表达与ROC SCS患者的手术结局和预测OS相关，因此值得进一步研究。
For recurrent ovarian cancer (ROC), secondary cytoreductive surgery (SCS) is recommended as one optional treatment. However, little is known about the expression and clinical significance of biomarkers during SCS. Human epididymis protein 4 (HE4) is a clinical biomarker for ovarian cancer. Eukaryotic translation initiation factor 3a (eIF3a) is investigated extensively as a potential biomarker for malignancy. The purpose of this study was to investigate the expressions of HE4 and eIF3a at SCS, as well as their associations with surgical outcome and survival in ROC patients. Immunohistochemistry was performed to determine the expressions of HE4 and eIF3a in ovarian tumors taken from both initial and secondary cytoreductive surgery of 35 ROC patients. eIF3a levels were significantly increased at SCS, compared to those at initial cytoreductive surgery (ICS), while HE4 levels were similar. Both HE4 and eIF3a expressions were associated with surgical outcome, in terms of residual tumor. For ICS, patients with high HE4 expression achieved a higher incidence of optimal cytoreduction than those with low HE4 expression (81.0% vs. 33.3%, P = 0.015). A similar result happened in SCS, indicated by higher incidence of no residual tumor in patients with high HE4 expression (76.4% vs. 44.4%, P = 0.046). And high HE4 expression at SCS was more likely to enhance surgical outcome of SCS (77.8% vs. 29.4%, P = 0.038). Therefore, high HE4 expression at either surgery is a predictor of better overall survival (OS) (P = 0.011 and 0.002). Furthermore, patients with an elevated total score (TS) of HE4 between the two surgeries tended to have prolonged OS, compared to those with a non-elevated TS of HE4 (P = 0.076). For eIF3a, initial eIF3a expression was associated with secondary residual tumor (P = 0.035), and the difference in eIF3a expression between the two surgeries correlated with OS (P = 0.052). The expressions of HE4 and eIF3a in tumor specimens correlated with surgical outcome and predicted OS in ROC patients with SCS, thus meriting further investigation.
登录
查看更多内容
影响因子：
2.1
作者：
Hauspy, Jan;Covens, Allan
通讯作者：
Covens, Allan
DOI：
10.1002/14651858.cd008765.pub3
发表时间：
2013-02-28
期刊：
The Cochrane database of systematic reviews
影响因子：
--
作者：
Al Rawahi, Thuria;Lopes, Alberto D;Galaal, Khadra
通讯作者：
Galaal, Khadra
影响因子：
3.7
作者：
Musella, A.;Marchetti, C.;Panici, P. Benedetti
通讯作者：
Panici, P. Benedetti
改变的 eIF3a 及其与 p27 在非小细胞肺癌中的关联的预后价值
影响因子：
3.7
作者：
Shen J;Yin JY;Li XP;Liu ZQ;Wang Y;Chen J;Qu J;Xu XJ;McLeod HL;He YJ;Xia K;Jia YW;Zhou HH
通讯作者：
Zhou HH
影响因子：
3.7
作者：
Angioli, Roberto;Capriglione, Stella;Plotti, Francesco
通讯作者：
Plotti, Francesco